Sina Eetezadi

390 Flips | 1 Magazine | 18 Likes | 139 Followers | @Eetezadi | Keep up with Sina Eetezadi on Flipboard, a place to see the stories, photos, and updates that matter to you. Flipboard creates a personalized magazine full of everything, from world news to life’s great moments. Download Flipboard for free and search for “Sina Eetezadi”

Roche's Stock May Have Been Down, But The Company's Business Has Strong Outlook

Roche’s stock fell following its full year 2015 earnings announcement, but the fundamentals remain strong. Here’s what worked for Roche last year, and why the outlook remains bright.<p><b>1) Roche’s 2015 revenue grew ~ 1%, but earnings fell ~ 5%</b><p>Note: Earnings fell due to currency impact, higher …

Roche Gets Breakthrough Therapy Designation From FDA for Multiple Sclerosis Treatment

Decision will likely speed up introduction of what is expected to be a blockbuster drug<p>ZURICH—Roche Holding AG said it has received breakthrough therapy designation from the U.S. Food and Drug Administration for a new multiple sclerosis treatment, likely speeding up the introduction of what is …

Multiple Sclerosis

Pfizer hikes U.S. prices for over 100 drugs on January 1 | Reuters

(Reuters) - Pfizer Inc (PFE.N), which plans a $160-billion merger with Ireland-based Allergan Plc (AGN.N) to slash its U.S. tax bill, on Jan. 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20 percent, according to statistics compiled by global information services company …

Pfizer

Big Pharma is having a harder and harder time cashing in on R&D

In 2010 Deloitte began following the top 12 pharmaceutical companies by R&D (or research and development) spending recorded the previous year. This 12-company cohort has since launched 186 products with estimated total revenue of $1.258 trillion, and it has collectively advanced 306 drug candidates …

Valeant CEO hospitalized for 'severe' pneumonia

The CEO of Valeant Pharmaceuticals is in the hospital with "severe" pneumonia, the company said Saturday.<p>J. Michael Pearson has been the head of Valeant (VRX) since 2008, leading the company during an aggressive expansion and merger. More recently, he's had to steer the company through some serious …

Time Warner

Merck wins approval for long-delayed surgery revival drug

WASHINGTON (AP) — Federal health authorities have approved a new drug that helps patients recover from the numbing effects of certain surgical …

Under fire for high prices, Valeant to sell some drugs for less at Walgreens

Stung by criticism that it jacked up the price of lifesaving medicines, Valeant Pharmaceuticals said Tuesday it will lower some prices though an agreement with Deerfield-based Walgreens, the nation's largest pharmacy retailer.<p>Valeant said its "fulfillment agreement" will cut prices by 10 percent on …

Health Care

AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion: WSJ | Reuters

(Reuters) - British drugmaker AstraZeneca Plc (AZN.L) is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion, the Wall Street Journal reported, citing people familiar with the matter.<p>A sign is seen at an AstraZeneca site in Macclesfield, central …

Brace yourself, pharma: 2016 will be 'the year of merger mania,' PwC says

A new report says 2016 will be "the year of merger mania." But does that mean industry watchers should expect to see more transactions in the …

Roche gets boost as multiple sclerosis drug works in big trials | Reuters

ZURICH, June 30 (Reuters) - A drug being developed by Roche to treat multiple sclerosis (MS) met main and secondary objectives in two studies, boosting the company’s hopes of expanding beyond its core cancer franchise.<p>The studies of MS treatment ocrelizumab showed the drug, which is injected, slows …

Debunking common myths about healthcare consumerism

Consumers are taking an increasingly active role in healthcare decision making. What does that mean for payors and providers? We separate fact from …

Israel's Teva and Takeda tie up for Japan generics business | FiercePharma

Japan's Takeda Pharmaceutical and Israel's Teva Pharmaceutical Industries ($TEVA) have decided to form a joint venture to take advantage of the …

Express Scripts Turns to a Compounder to Avoid a Turing Drug

Imprimis will supply a $1 version of Daraprim after Turing jacks up price<p>Drug-benefit manager Express Scripts Holding Co. said it is making arrangements with a drug compounder for patients to receive a lower-priced alternative to the expensive anti-parasitic pill Daraprim, whose price jumped more …

Pharma

Dr. Patrick Soon-Shiong is postponing IPO of healthcare data company NantHealth

Dr. Patrick Soon-Shiong, the billionaire L.A. medical entrepreneur, is postponing the planned initial public offering of his healthcare data company, NantHealth.<p>The news comes five months after Soon-Shiong told The Times that he planned to take the Culver City company public by the end of this year.<p>…

Market Capitalization

Mylan may soon find itself wrestling former target Perrigo for deals

Earlier this month, Perrigo shareholders spurned a hostile buyout attempt from Mylan. And now, the Netherlands-based company may have to go up …

Spurned Shire preps new takeover offer for longtime target Baxalta

Last month, Shire said it still believed an acquisition for Baxalta--a target that rejected it almost four months back--would make a "highly …

The Pfizer-Allergan Deal Shouldn’t Be Just About Tax Inversion

<i>HBR STAFF</i><p>Pfizer and Allergan are set to merge in the biggest combination of the year, valued at $160 billion. It is big in terms of the total corporate assets that are being re-assigned to new owners. But is it also big in terms of the joint value that will likely be created?<p>The size of a merger …

Innovation

Pfizer Says No Merger Tax Help For Our Top Execs

When Pfizer Inc. (PFE) completes its merger with Botox maker Allergan PLC (AGN) in the second half of next year, most of its shareholders will be hit …

Pfizer and Allergan agree on $160bn deal to create world's biggest pharma firm

Viagra maker Pfizer has agreed to a merger with Botox maker Allergan. The deal has been priced at $160bn (£106bn, €150bn) and will create the world's …

EU approves Roche's Cotellic in combo therapy against skin cancer | Reuters

ZURICH (Reuters) - The European Union gave its green light to Roche’s Cotellic for use in combination with the drug Zelboraf against advanced melanoma, the company said on Wednesday.<p>Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland October 22, 2015. REUTERS/Arnd …

While Big Pharma does deals, local biotech firms blaza trails on research

The blockbuster business news Monday was Pfizer Inc.’s $155 billion takeover of Allergan PLC, a deal that would create the world’s largest drug …

Ernst & Young

Pfizer Said Near Allergan Deal as U.S. Targets Inversions

Pfizer Inc. is in advanced talks to buy Allergan Plc for as much as $380 per share, according to people familiar with the matter, valuing the Botox …

Can Pharma Clean Up Its Act on Drug Pricing? Q&A With Alnylam CEO John Maraganore

[<i>Note: This interview originally appeared on Timmerman Report, a subscription publication for biotech insiders</i>.]<p>At an event I moderated last week in Boston, one company bailed out when I insisted on talking about drug pricing. This is not the time to hide. We need to talk.<p>Recent drug-pricing …

Roche breast cancer drug at center of UK pricing row

A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the center of a drug pricing row after Britain's health cost agency declared that it is still too expensive.<p>The stand-off shows how the price of medicines is as pressing and emotive an issue …

Global Drug Spending Will Reach $1.4 Trillion by 2020

Global spending on medicines is expected to grow as much as 32% over the next five years to hit $1.4 trillion in 2020, according to research released …

Pfizer-Allergan Deal is Contingent Upon Saunders Becoming CEO

November 17, 2015<br>By Mark Terry, BioSpace.com Breaking News Staff<p>With a <b>Pfizer Inc.</b> (<b>PFE</b>)-<b>Allergan Inc.</b> (<b>AGN</b>) deal facing a self-imposed announcement</b> …

Digital Strategy to Drive Growth

Overview<p>Latest Thinking<p>Client Case Studies<p>LEADERSHIP<p><i>“Digital business is changing expectations and shifting value within and across industries,</i> …